MeSH term
Frequency | Condition_Probility | Acute Disease | 10 | 0.0 |
Adult | 503 | 0.0 |
Comparative Study | 166 | 0.0 |
Humans | 1271 | 0.0 |
Albumins/metabolism | 4 | 2.0 |
Albuminuria/*prevention & control | 2 | 2.0 |
Antihypertensive Agents/*therapeutic use | 2 | 0.0 |
Diabetes Mellitus, Type 2/complications/*drug therapy | 2 | 2.0 |
Hypertension/complications/*drug therapy | 2 | 1.0 |
Indoles/*therapeutic use | 2 | 1.0 |
Renin-Angiotensin System/*drug effects | 2 | 1.0 |
Animals | 365 | 0.0 |
Finland | 6 | 2.0 |
African Continental Ancestry Group | 3 | 1.0 |
United States | 4 | 0.0 |
Apolipoproteins C/*genetics | 10 | 11.0 |
Apolipoproteins E/*genetics | 19 | 2.0 |
Brazil | 5 | 2.0 |
Indians, South American/*genetics | 2 | 3.0 |
Linkage Disequilibrium | 17 | 2.0 |
Lipoprotein Lipase/*genetics | 169 | 94.0 |
*Multigene Family | 4 | 0.0 |
Research Support, Non-U.S. Gov't | 844 | 0.0 |
*Variation (Genetics) | 17 | 1.0 |
Chromosomes, Human, Pair 8/*genetics | 4 | 3.0 |
Cohort Studies | 31 | 1.0 |
Disease Progression | 8 | 0.0 |
Genetic Markers/genetics | 6 | 1.0 |
Male | 663 | 0.0 |
Survival Rate | 2 | 0.0 |
Amino Acid Substitution | 7 | 0.0 |
Base Sequence | 160 | 0.0 |
DNA Primers | 22 | 0.0 |
Electrophoresis, Agar Gel | 8 | 1.0 |
Female | 560 | 0.0 |
Genotype | 104 | 1.0 |
Glutamic Acid/*genetics | 2 | 20.0 |
Hyperlipidemia/*genetics | 5 | 22.0 |
Lipoprotein Lipase/genetics | 23 | 76.0 |
Lysine/*genetics | 2 | 15.0 |
Middle Aged | 429 | 0.0 |
Phenotype | 44 | 0.0 |
Polymerase Chain Reaction | 94 | 0.0 |
Polymorphism, Restriction Fragment Length | 30 | 1.0 |
Anticholesteremic Agents/therapeutic use | 2 | 6.0 |
Antilipemic Agents/*therapeutic use | 5 | 6.0 |
Cholesterol/blood | 127 | 10.0 |
DNA/analysis | 10 | 1.0 |
Double-Blind Method | 16 | 0.0 |
*Polymorphism, Genetic | 47 | 1.0 |
Promoter Regions (Genetics) | 15 | 0.0 |
Triglycerides/blood | 207 | 15.0 |
Aged | 177 | 0.0 |
Analysis of Variance | 24 | 1.0 |
Biological Markers/analysis | 2 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 20 | 0.0 |
Heparin/pharmacology | 54 | 22.0 |
Lipoprotein Lipase/*blood/genetics/metabolism | 2 | 100.0 |
Lipoproteins, HDL Cholesterol/*blood | 34 | 15.0 |
Lipoproteins, LDL Cholesterol/*blood | 8 | 9.0 |
Polymorphism, Genetic | 33 | 0.0 |
Probability | 8 | 1.0 |
Prospective Studies | 12 | 0.0 |
Risk Assessment | 5 | 0.0 |
Sensitivity and Specificity | 15 | 0.0 |
Severity of Illness Index | 4 | 0.0 |
Statistics, Nonparametric | 10 | 0.0 |
Adipocytes/*enzymology | 4 | 44.0 |
Adipose Tissue/*enzymology | 45 | 81.0 |
Cells, Cultured | 99 | 0.0 |
Cholesterol Esterase/*metabolism | 4 | 80.0 |
Dihydrotestosterone/*pharmacology | 2 | 6.0 |
Lipoprotein Lipase/*metabolism | 175 | 91.0 |
Gene Frequency | 53 | 1.0 |
Lipids/blood/genetics | 2 | 50.0 |
Lipoproteins/blood/genetics | 2 | 40.0 |
*Mutation | 52 | 1.0 |
Polymorphism, Genetic/*genetics | 11 | 0.0 |
Receptors, Cytoplasmic and Nuclear/*genetics | 2 | 2.0 |
Risk Factors | 63 | 1.0 |
Transcription Factors/*genetics | 2 | 0.0 |
Triglycerides/blood/genetics | 3 | 37.0 |
Adolescent | 81 | 0.0 |
Child | 39 | 0.0 |
DNA/*analysis | 6 | 2.0 |
Polymerase Chain Reaction/methods | 8 | 0.0 |
Tandem Repeat Sequences/*genetics | 7 | 7.0 |
Apolipoproteins E/genetics | 17 | 5.0 |
Body Composition | 14 | 5.0 |
Body Weight/physiology | 2 | 2.0 |
Carrier Proteins/*genetics | 8 | 0.0 |
Diet, Fat-Restricted | 3 | 15.0 |
European Continental Ancestry Group | 9 | 1.0 |
Exercise/*physiology | 13 | 3.0 |
*Glycoproteins | 44 | 5.0 |
Lipoproteins, LDL Cholesterol/blood | 35 | 6.0 |
Magnetic Resonance Spectroscopy | 2 | 0.0 |
Oxygen Consumption | 7 | 2.0 |
Research Support, U.S. Gov't, P.H.S. | 386 | 0.0 |
Tomography, X-Ray Computed | 2 | 0.0 |
Variation (Genetics) | 19 | 1.0 |
Adipose Tissue/*metabolism | 27 | 25.0 |
Diabetes Mellitus, Type 2/metabolism | 2 | 7.0 |
*Gene Expression | 9 | 0.0 |
Insulin/blood | 46 | 6.0 |
Insulin Resistance | 8 | 4.0 |
Lipoproteins, HDL Cholesterol/blood | 74 | 10.0 |
Lipoproteins, VLDL Cholesterol/blood | 14 | 22.0 |
Obesity/*metabolism | 10 | 13.0 |
RNA, Messenger/analysis | 23 | 0.0 |
Cell Membrane/metabolism | 7 | 0.0 |
Cross-Over Studies | 13 | 2.0 |
Fatty Acids/metabolism | 14 | 11.0 |
Fatty Acids, Unsaturated/*pharmacology | 2 | 6.0 |
Lipids/blood/metabolism | 2 | 18.0 |
Lipoprotein Lipase/blood/*genetics/metabolism | 2 | 100.0 |
Lipoproteins/blood/*metabolism | 8 | 25.0 |
RNA, Messenger/metabolism | 24 | 0.0 |
Apolipoproteins C/metabolism | 9 | 69.0 |
Lipase/*metabolism | 30 | 52.0 |
Lipolysis | 46 | 53.0 |
Lipoprotein Lipase/metabolism | 81 | 80.0 |
Lipoproteins/metabolism | 22 | 20.0 |
Dose-Response Relationship, Drug | 26 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 28 | 0.0 |
Immunoblotting | 10 | 0.0 |
Lipoprotein Lipase/genetics/*metabolism | 29 | 93.0 |
Lipoproteins, LDL/*pharmacokinetics | 2 | 22.0 |
Mice | 153 | 0.0 |
Mice, Knockout | 20 | 0.0 |
Milk | 2 | 10.0 |
Swine | 11 | 0.0 |
Time Factors | 59 | 0.0 |
Up-Regulation | 8 | 0.0 |
Apolipoproteins E/genetics/metabolism | 3 | 12.0 |
Carrier Proteins/genetics/metabolism | 2 | 1.0 |
*Haplotypes | 2 | 0.0 |
Lipoprotein Lipase/genetics/metabolism | 6 | 60.0 |
Lipoproteins, HDL/blood/*metabolism | 3 | 27.0 |
Polymorphism, Single Nucleotide | 4 | 0.0 |
Receptors, LDL/genetics/metabolism | 2 | 9.0 |
Structure-Activity Relationship | 29 | 0.0 |
Blood Glucose/metabolism | 29 | 4.0 |
Dietary Carbohydrates/pharmacology | 4 | 23.0 |
Fatty Acids, Nonesterified/blood | 41 | 21.0 |
Gene Expression Regulation/*physiology | 2 | 0.0 |
Metabolism/*genetics | 2 | 33.0 |
Muscle, Skeletal/*metabolism | 9 | 5.0 |
Oxygen Consumption/physiology | 3 | 4.0 |
Reverse Transcriptase Polymerase Chain Reaction | 14 | 0.0 |
Heterozygote | 53 | 1.0 |
Lipids/blood | 65 | 10.0 |
Lipoprotein Lipase/*deficiency/*genetics | 13 | 92.0 |
Lipoproteins/blood | 65 | 16.0 |
Multivariate Analysis | 12 | 0.0 |
Particle Size | 21 | 7.0 |
Sex Characteristics | 15 | 2.0 |
Blood Glucose/*metabolism | 3 | 1.0 |
Homozygote | 26 | 1.0 |
Hypertriglyceridemia/*etiology | 7 | 63.0 |
Insulin/*secretion | 2 | 2.0 |
Lipoprotein Lipase Deficiency, Familial/*complications | 2 | 100.0 |
Mutation | 56 | 0.0 |
Sequence Analysis, DNA | 8 | 0.0 |
Chylomicrons/*blood | 22 | 73.0 |
Hypertriglyceridemia/*genetics | 5 | 41.0 |
Infant | 21 | 0.0 |
Lipoprotein Lipase Deficiency, Familial/*genetics | 14 | 100.0 |
Pregnancy | 28 | 0.0 |
*Pregnancy Complications | 5 | 12.0 |
Pregnancy Outcome | 2 | 0.0 |
Apolipoprotein A-I/blood | 8 | 7.0 |
Apolipoproteins B/blood | 19 | 7.0 |
Biological Transport | 18 | 1.0 |
Carrier Proteins/blood | 15 | 14.0 |
Cholesterol Esters/*blood | 5 | 6.0 |
Endothelium, Vascular/physiology | 3 | 4.0 |
*Estrogen Replacement Therapy | 3 | 2.0 |
Food | 3 | 2.0 |
Lipoprotein Lipase/blood | 56 | 70.0 |
Lipoproteins, LDL/blood | 31 | 13.0 |
Membrane Proteins/blood | 4 | 10.0 |
*Phospholipid Transfer Proteins | 7 | 4.0 |
Adipose Tissue/drug effects/*metabolism | 6 | 37.0 |
Drug Synergism | 4 | 0.0 |
Glycerol/metabolism | 5 | 12.0 |
Hypoglycemic Agents/*pharmacology | 3 | 6.0 |
In Vitro | 36 | 0.0 |
Insulin/*pharmacology | 11 | 5.0 |
Lipolysis/*drug effects | 19 | 63.0 |
Norepinephrine/pharmacology | 5 | 6.0 |
Thiazoles/*pharmacology | 3 | 5.0 |
*Thiazolidinediones | 6 | 6.0 |
Aged, 80 and over | 22 | 0.0 |
Case-Control Studies | 30 | 0.0 |
Dietary Fats | 5 | 13.0 |
Japan/epidemiology | 4 | 1.0 |
Abdomen | 19 | 22.0 |
Adipose Tissue/enzymology | 25 | 83.0 |
*Body Constitution | 4 | 14.0 |
Body Mass Index | 44 | 4.0 |
Obesity/*physiopathology | 2 | 3.0 |
Repetitive Sequences, Nucleic Acid | 6 | 0.0 |
Genetic Predisposition to Disease | 20 | 0.0 |
Logistic Models | 4 | 0.0 |
Magnetic Resonance Imaging | 3 | 0.0 |
Predictive Value of Tests | 5 | 0.0 |
Proportional Hazards Models | 2 | 0.0 |
Cell Line | 65 | 0.0 |
Enzyme Activation | 21 | 0.0 |
Gene Expression Regulation/*drug effects | 4 | 0.0 |
Macrophages/drug effects/*metabolism | 3 | 5.0 |
Protein Kinase C/*metabolism | 3 | 1.0 |
RNA, Messenger/genetics | 13 | 0.0 |
Muscle, Skeletal/*enzymology | 10 | 22.0 |
Rats | 78 | 0.0 |
Triglycerides/blood/*metabolism | 8 | 44.0 |
Anticoagulants/*administration & dosage | 4 | 9.0 |
Blood Glucose | 5 | 6.0 |
Guinea Pigs | 12 | 1.0 |
Heparin/*administration & dosage | 7 | 22.0 |
Myocardium/enzymology | 7 | 8.0 |
DNA/*genetics | 2 | 0.0 |
Deoxyribonuclease HindIII | 13 | 31.0 |
Diabetes Mellitus, Type 1/complications | 2 | 11.0 |
English Abstract | 52 | 0.0 |
Lipoprotein Lipase/*genetics/metabolism | 32 | 100.0 |
Molecular Biology | 4 | 1.0 |
Gene Expression Regulation, Enzymologic | 11 | 1.0 |
Lipoprotein Lipase/blood/genetics/*metabolism | 4 | 100.0 |
RNA, Messenger/genetics/metabolism | 10 | 0.0 |
Cercopithecus aethiops | 7 | 0.0 |
*Alanine | 2 | 11.0 |
Alleles | 74 | 0.0 |
Deoxyribonucleases, Type II Site-Specific | 7 | 2.0 |
Culture Media, Conditioned | 7 | 2.0 |
Gene Expression | 24 | 0.0 |
Lipids/*metabolism | 28 | 12.0 |
Macrophages/*enzymology/metabolism | 2 | 40.0 |
RNA, Messenger/biosynthesis | 7 | 0.0 |
Area Under Curve | 6 | 1.0 |
Dietary Fats/*administration & dosage | 12 | 14.0 |
Leucine/*genetics | 2 | 8.0 |
Lipase/metabolism | 20 | 38.0 |
Lipids/*blood | 66 | 11.0 |
Postprandial Period | 17 | 18.0 |
Proline/*genetics | 3 | 15.0 |
Cell Differentiation | 12 | 0.0 |
Lipoproteins, LDL/*metabolism | 22 | 11.0 |
Monocytes/cytology/*metabolism | 2 | 7.0 |
Lipoprotein Lipase/*antagonists & inhibitors | 13 | 92.0 |
Mice, Inbred BALB C | 6 | 0.0 |
Mice, Nude | 4 | 0.0 |
Neoplasm Transplantation | 3 | 0.0 |
Propranolol/pharmacology | 2 | 4.0 |
Tumor Cells, Cultured | 27 | 0.0 |
Arteriosclerosis/*metabolism | 3 | 4.0 |
Endothelium, Vascular/metabolism | 2 | 0.0 |
Extracellular Matrix/*metabolism | 2 | 2.0 |
*African Continental Ancestry Group | 2 | 1.0 |
*Ethnic Groups | 2 | 1.0 |
*European Continental Ancestry Group | 2 | 2.0 |
Lipoprotein Lipase/*blood/genetics | 3 | 100.0 |
*Postprandial Period | 5 | 17.0 |
Triglycerides/*blood | 76 | 20.0 |
Genetic Predisposition to Disease/*genetics | 5 | 1.0 |
Genome, Human | 2 | 0.0 |
Linkage (Genetics) | 6 | 0.0 |
Lod Score | 5 | 0.0 |
Microsatellite Repeats | 5 | 0.0 |
Chromosomes, Human, Pair 8 | 8 | 6.0 |
Genetic Markers | 13 | 0.0 |
In Situ Hybridization, Fluorescence | 3 | 0.0 |
Retrospective Studies | 5 | 0.0 |
Adenosine Triphosphate/metabolism | 3 | 0.0 |
Blotting, Western | 18 | 0.0 |
CHO Cells | 26 | 1.0 |
Calnexin | 2 | 6.0 |
Carrier Proteins/metabolism | 4 | 0.0 |
Centrifugation, Density Gradient | 8 | 2.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
Dimerization | 9 | 0.0 |
Disulfides | 2 | 2.0 |
Endoplasmic Reticulum/*enzymology | 3 | 10.0 |
Hamsters | 31 | 0.0 |
Heparin/*metabolism | 13 | 15.0 |
Lipoprotein Lipase/*chemistry/*metabolism | 2 | 100.0 |
Oxidation-Reduction | 19 | 1.0 |
Precipitin Tests | 4 | 0.0 |
Protein Binding | 45 | 0.0 |
Protein Conformation | 13 | 0.0 |
Protein Folding | 4 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 74 | 0.0 |
Solubility | 2 | 0.0 |
Transfection | 50 | 0.0 |
Adipocytes/metabolism | 3 | 7.0 |
Adipose Tissue/cytology/*metabolism | 7 | 46.0 |
Gene Expression Regulation | 14 | 0.0 |
*Weight Loss | 6 | 12.0 |
Adipose Tissue/metabolism | 23 | 18.0 |
Apolipoproteins B/metabolism | 11 | 12.0 |
Blotting, Northern | 34 | 0.0 |
Body Weight | 28 | 4.0 |
Chromatography, High Pressure Liquid | 11 | 0.0 |
Glucose/metabolism | 8 | 3.0 |
Hypertriglyceridemia/genetics | 7 | 46.0 |
Kinetics | 86 | 1.0 |
Lipoprotein Lipase/blood/*metabolism | 9 | 100.0 |
Mice, Transgenic | 38 | 1.0 |
Muscles/metabolism | 5 | 5.0 |
Protein Structure, Tertiary | 3 | 0.0 |
Protein Transport | 2 | 0.0 |
Tissue Distribution | 11 | 0.0 |
Acetylcholine/pharmacology | 2 | 2.0 |
Fatty Acids, Nonesterified/analysis | 3 | 37.0 |
Lipoprotein Lipase/biosynthesis/*genetics | 8 | 100.0 |
Myocardium/metabolism | 9 | 3.0 |
Nitroprusside/pharmacology | 2 | 2.0 |
Organ Specificity | 11 | 0.0 |
Biological Transport/drug effects | 3 | 1.0 |
Depression, Chemical | 2 | 1.0 |
Glucose/*metabolism | 3 | 1.0 |
Lipolysis/drug effects | 18 | 60.0 |
Hypertriglyceridemia/metabolism | 2 | 28.0 |
Lipoprotein Lipase/deficiency/*metabolism | 2 | 100.0 |
Rats, Mutant Strains | 2 | 3.0 |
Rats, Sprague-Dawley | 15 | 0.0 |
Receptors, LDL/deficiency/*metabolism | 2 | 66.0 |
Lipoproteins/*blood | 77 | 12.0 |
Lipoproteins, HDL/blood | 43 | 16.0 |
Lipoproteins, VLDL/blood | 42 | 18.0 |
Syndrome | 5 | 0.0 |
Chylomicrons/pharmacokinetics | 2 | 100.0 |
Crosses, Genetic | 2 | 0.0 |
Hydrolysis | 37 | 4.0 |
Lipids/metabolism | 28 | 8.0 |
Mice, Mutant Strains | 5 | 0.0 |
Microscopy, Electron | 9 | 0.0 |
Microscopy, Fluorescence | 5 | 0.0 |
Child, Preschool | 30 | 0.0 |
Family Health | 4 | 0.0 |
Hyperinsulinism/*genetics | 2 | 20.0 |
Insulin Resistance/genetics | 3 | 7.0 |
Japan | 12 | 0.0 |
Mutation/*genetics | 13 | 1.0 |
Pedigree | 65 | 0.0 |
Cloning, Molecular | 27 | 0.0 |
Lipoproteins, VLDL/metabolism | 17 | 16.0 |
Receptors, LDL/*physiology | 3 | 33.0 |
Signal Transduction | 5 | 0.0 |
Lipoproteins/*metabolism | 27 | 17.0 |
Postprandial Period/*physiology | 11 | 34.0 |
Regression Analysis | 21 | 1.0 |
Triglycerides/*metabolism | 23 | 27.0 |
Carrier Proteins/*analysis | 2 | 2.0 |
Cell Membrane/enzymology | 2 | 0.0 |
Pregnancy in Diabetics/*metabolism | 2 | 22.0 |
Triglycerides/metabolism | 43 | 26.0 |
*Gene Therapy | 2 | 0.0 |
Gene Transfer Techniques | 5 | 0.0 |
Genetic Vectors | 7 | 0.0 |
Injections, Intramuscular | 2 | 1.0 |
Coronary Angiography | 13 | 5.0 |
Electrocardiography | 2 | 0.0 |
Exercise Test | 4 | 1.0 |
Follow-Up Studies | 9 | 0.0 |
Molecular Sequence Data | 168 | 0.0 |
Cross-Sectional Studies | 7 | 0.0 |
Serine/*genetics | 3 | 15.0 |
Triglycerides/*analysis | 2 | 40.0 |
Catalysis | 23 | 2.0 |
Circular Dichroism | 2 | 0.0 |
Mutagenesis, Site-Directed | 30 | 1.0 |
Apolipoproteins E/metabolism | 10 | 15.0 |
Heptanoic Acids/*therapeutic use | 2 | 8.0 |
Hyperlipidemia/*drug therapy/*enzymology | 2 | 100.0 |
Lipoprotein Lipase/*blood | 89 | 87.0 |
Pyrroles/*therapeutic use | 2 | 5.0 |
Cholesterol Esters/blood | 13 | 10.0 |
Coronary Disease/genetics | 2 | 5.0 |
Esterification | 6 | 7.0 |
Fasting | 27 | 8.0 |
Gestational Age | 3 | 0.0 |
Aging | 6 | 1.0 |
Apolipoproteins B/blood/genetics | 2 | 33.0 |
Apolipoproteins C/genetics | 9 | 25.0 |
Codon | 3 | 0.0 |
Smoking | 5 | 1.0 |
HELLP Syndrome/genetics | 2 | 50.0 |
*Point Mutation | 16 | 1.0 |
Energy Metabolism | 12 | 6.0 |
Gene Frequency/genetics | 5 | 1.0 |
Spain | 2 | 0.0 |
*Genetics, Population | 8 | 2.0 |
Models, Genetic | 9 | 0.0 |
Quebec/epidemiology | 3 | 10.0 |
Macrophages/*metabolism | 16 | 6.0 |
Mice, Inbred C57BL | 26 | 0.0 |
*Transcription, Genetic | 5 | 0.0 |
Monosaccharide Transport Proteins/genetics | 2 | 12.0 |
*Muscle Proteins | 5 | 1.0 |
Receptors, Cytoplasmic and Nuclear/genetics | 2 | 5.0 |
Transcription Factors/genetics | 2 | 0.0 |
Blood Pressure/*genetics | 7 | 12.0 |
Hypertension/blood/complications/genetics | 2 | 100.0 |
*Polymorphism, Single Nucleotide | 11 | 2.0 |
Population Surveillance | 3 | 1.0 |
Reference Values | 55 | 1.0 |
Life Expectancy | 2 | 4.0 |
Myocardial Infarction/enzymology/*genetics | 2 | 25.0 |
Culture Techniques | 5 | 1.0 |
Arteriosclerosis/metabolism | 3 | 5.0 |
*Alleles | 8 | 0.0 |
Arginine/*genetics | 2 | 3.0 |
*DNA Mutational Analysis | 2 | 1.0 |
Genetic Predisposition to Disease/genetics | 4 | 0.0 |
Heterozygote Detection | 7 | 1.0 |
Obesity/*genetics | 3 | 2.0 |
Receptors, Adrenergic, beta-3/*genetics | 2 | 10.0 |
Sex Factors | 24 | 1.0 |
Tryptophan/*genetics | 3 | 30.0 |
Adipose Tissue/*anatomy & histology | 2 | 3.0 |
Anthropometry | 6 | 2.0 |
Blotting, Southern | 16 | 0.0 |
Molecular Weight | 17 | 0.0 |
Quebec | 9 | 16.0 |
Adipose Tissue/physiopathology | 2 | 33.0 |
Energy Metabolism/physiology | 5 | 8.0 |
Treatment Outcome | 6 | 0.0 |
Electrophoresis | 4 | 1.0 |
Cell Adhesion | 5 | 0.0 |
Diet | 13 | 3.0 |
Diet, Atherogenic | 3 | 9.0 |
Exons | 27 | 0.0 |
*Gene Expression Regulation, Enzymologic | 7 | 1.0 |
Introns | 12 | 0.0 |
Lipoprotein Lipase/*genetics/*metabolism | 9 | 100.0 |
Liver/enzymology/metabolism | 4 | 12.0 |
Macrophages/enzymology/metabolism | 2 | 50.0 |
Trans-Activation (Genetics) | 3 | 0.0 |
Chi-Square Distribution | 5 | 0.0 |
Introns/*genetics | 2 | 1.0 |
Amino Acid Sequence | 86 | 0.0 |
Lipoprotein Lipase/*chemistry/genetics | 2 | 100.0 |
Mutagenesis | 6 | 0.0 |
Pancreas/enzymology | 5 | 13.0 |
Sequence Homology, Amino Acid | 14 | 0.0 |
Infusions, Intravenous | 5 | 0.0 |
Liver/enzymology | 67 | 11.0 |
Partial Thromboplastin Time | 8 | 4.0 |
Chylomicrons/metabolism | 8 | 34.0 |
Intestinal Absorption | 2 | 1.0 |
Liver/metabolism | 17 | 2.0 |
Molecular Structure | 3 | 0.0 |
Anticoagulants/*pharmacology | 2 | 2.0 |
Heparin/*pharmacology | 25 | 17.0 |
Glucose Tolerance Test | 11 | 2.0 |
Insulin/*blood | 12 | 6.0 |
Animals, Genetically Modified | 7 | 2.0 |
Apolipoproteins/blood | 38 | 16.0 |
Arteriosclerosis/*genetics | 4 | 14.0 |
Hypercholesterolemia/*genetics | 3 | 16.0 |
Lipoprotein Lipase/*biosynthesis/genetics | 6 | 100.0 |
Rabbits | 18 | 0.0 |
Recombinant Proteins/biosynthesis | 3 | 0.0 |
Hormones/physiology | 2 | 6.0 |
Obesity/physiopathology | 2 | 7.0 |
Weight Loss | 4 | 2.0 |
Arteriosclerosis/*etiology | 2 | 5.0 |
Hypercholesterolemia/complications | 2 | 16.0 |
Liver/*enzymology | 67 | 14.0 |
Lipoprotein Lipase/chemistry/*genetics | 6 | 100.0 |
Longitudinal Studies | 3 | 0.0 |
Point Mutation/genetics | 4 | 1.0 |
*Membrane Transport Proteins | 2 | 0.0 |
*Mitochondrial Proteins | 2 | 1.0 |
Enzyme Induction | 5 | 0.0 |
Hydrocortisone/blood | 2 | 0.0 |
Insulin-Like Growth Factor I/physiology | 3 | 9.0 |
Lipoprotein Lipase/biosynthesis/*metabolism | 3 | 100.0 |
Antilipemic Agents/pharmacology | 2 | 14.0 |
Ligands | 6 | 0.0 |
Lipoprotein Lipase/antagonists & inhibitors/*metabolism | 3 | 100.0 |
Myocardium/*enzymology | 6 | 7.0 |
Receptors, Cytoplasmic and Nuclear/*metabolism | 2 | 1.0 |
Transcription Factors/*metabolism | 4 | 0.0 |
Consanguinity | 5 | 1.0 |
Linear Models | 4 | 0.0 |
Variation (Genetics)/*genetics | 4 | 1.0 |
Genes | 2 | 0.0 |
COS Cells | 8 | 0.0 |
DNA, Complementary/*genetics | 2 | 0.0 |
Exons/genetics | 6 | 0.0 |
Introns/genetics | 6 | 0.0 |
Lipase/blood | 39 | 53.0 |
Lipoprotein Lipase/blood/*genetics | 23 | 100.0 |
Mutation/genetics | 6 | 0.0 |
Blood Glucose/analysis | 27 | 4.0 |
Dietary Fats/metabolism | 6 | 18.0 |
*Exercise | 6 | 4.0 |
Muscle, Skeletal/enzymology/*metabolism | 2 | 20.0 |
Triglycerides/analysis/blood | 2 | 40.0 |
Receptors, LDL/metabolism | 11 | 11.0 |
Recombinant Proteins/chemistry/metabolism | 6 | 0.0 |
Apolipoproteins/*genetics | 6 | 8.0 |
Arteriosclerosis/etiology/*genetics | 3 | 75.0 |
Obesity/blood/*genetics | 2 | 15.0 |
Cattle | 61 | 2.0 |
Endothelium, Vascular/drug effects/*metabolism | 4 | 5.0 |
Protein Binding/drug effects | 2 | 0.0 |
Haplotypes/genetics | 2 | 0.0 |
Polymorphism, Single-Stranded Conformational | 10 | 0.0 |
Acetylation | 3 | 0.0 |
Endothelium, Vascular/*metabolism | 5 | 1.0 |
Fibroblasts/*metabolism | 3 | 1.0 |
Heparin/blood | 5 | 35.0 |
Point Mutation/*genetics | 6 | 2.0 |
Recurrence | 6 | 0.0 |
*Chromosome Deletion | 3 | 0.0 |
Alcohol Drinking | 3 | 2.0 |
*Heterozygote | 13 | 4.0 |
Insulin/*metabolism | 2 | 2.0 |
Age Distribution | 2 | 0.0 |
Asian Continental Ancestry Group/*genetics | 5 | 1.0 |
Canada/epidemiology | 2 | 5.0 |
China/ethnology | 2 | 1.0 |
Incidence | 3 | 0.0 |
Lipoproteins, HDL Cholesterol/*metabolism | 9 | 25.0 |
Sex Distribution | 2 | 0.0 |
Adipose Tissue/*chemistry | 2 | 14.0 |
Lipoprotein Lipase Deficiency, Familial/genetics/*metabolism | 2 | 100.0 |
Mutation, Missense | 6 | 0.0 |
Alu Elements/genetics | 2 | 7.0 |
Evolution, Molecular | 2 | 0.0 |
Genetics, Population | 5 | 1.0 |
Mutagenesis, Insertional/genetics | 2 | 8.0 |
Discriminant Analysis | 2 | 2.0 |
European Continental Ancestry Group/genetics | 9 | 1.0 |
Gene Frequency/*genetics | 3 | 2.0 |
Minisatellite Repeats/*genetics | 2 | 2.0 |
Paternity | 2 | 2.0 |
Poland | 4 | 2.0 |
Polymorphism, Genetic/genetics | 7 | 1.0 |
Apolipoprotein A-I/*metabolism | 2 | 4.0 |
Diabetes Mellitus, Type 2/*metabolism | 3 | 6.0 |
Lipoprotein Lipase/*physiology | 15 | 83.0 |
Lipoproteins, HDL/metabolism | 5 | 4.0 |
Binding Sites/genetics | 2 | 0.0 |
Chromatography, Affinity | 20 | 2.0 |
Enzyme Stability | 6 | 3.0 |
Fat Emulsions, Intravenous/metabolism | 4 | 100.0 |
Heparan Sulfate Proteoglycan/*metabolism | 4 | 25.0 |
Muscles/metabolism/pathology | 2 | 25.0 |
Palmitates/metabolism | 2 | 20.0 |
Cardiovascular Diseases/blood/*genetics | 3 | 25.0 |
France | 5 | 1.0 |
Italy | 6 | 0.0 |
Lipoprotein Lipase/chemistry/*deficiency/*genetics | 2 | 100.0 |
*Mutation, Missense | 6 | 1.0 |
Sequence Deletion | 3 | 0.0 |
Dietary Carbohydrates | 3 | 13.0 |
Insulin Resistance/*physiology | 6 | 8.0 |
Muscle, Skeletal/*physiology | 2 | 2.0 |
Triglycerides/blood/metabolism | 5 | 22.0 |
Apolipoproteins B/*metabolism | 8 | 8.0 |
Heparin/metabolism | 19 | 15.0 |
Liposomes | 2 | 0.0 |
Cholesterol/*blood | 12 | 4.0 |
DNA Mutational Analysis | 16 | 0.0 |
Prevalence | 11 | 0.0 |
DNA, Complementary/genetics | 6 | 0.0 |
Gene Expression Profiling | 3 | 0.0 |
Intestines/metabolism | 3 | 2.0 |
Tetradecanoylphorbol Acetate/pharmacology | 5 | 0.0 |
Transcription, Genetic/drug effects | 2 | 0.0 |
Diabetes Mellitus, Type 2/*blood | 5 | 4.0 |
Hemoglobin A, Glycosylated/analysis | 5 | 1.0 |
*Insulin Resistance | 10 | 5.0 |
Lipase/*blood | 43 | 70.0 |
Dietary Fats/pharmacology | 3 | 8.0 |
Gastric Inhibitory Polypeptide/blood | 2 | 5.0 |
Glucagon/blood | 6 | 6.0 |
Obesity/*enzymology | 6 | 54.0 |
Hyperlipidemia/genetics | 2 | 12.0 |
Apolipoproteins/metabolism | 3 | 7.0 |
Lipoprotein Lipase Deficiency, Familial/genetics/physiopathology | 2 | 100.0 |
Fatty Acids/*administration & dosage | 3 | 30.0 |
Consensus Sequence | 2 | 0.0 |
Immunologic Techniques | 3 | 0.0 |
Macrophages/*enzymology | 8 | 25.0 |
Nuclear Proteins/metabolism | 2 | 0.0 |
Coronary Arteriosclerosis/blood/*enzymology/*genetics | 2 | 100.0 |
Haplotypes | 21 | 0.0 |
Netherlands | 4 | 2.0 |
Polymerase Chain Reaction/*methods | 6 | 1.0 |
Reproducibility of Results | 9 | 0.0 |
Arteriosclerosis/genetics | 3 | 10.0 |
Epistasis, Genetic | 2 | 3.0 |
Lipids/*blood/metabolism | 4 | 33.0 |
Age of Onset | 3 | 0.0 |
*Life Style | 2 | 3.0 |
Myocardial Infarction/blood/*genetics | 2 | 15.0 |
Omentum | 5 | 31.0 |
Lipoproteins/*blood/metabolism | 3 | 23.0 |
Hyperlipoproteinemia/*genetics | 3 | 27.0 |
Survivors | 3 | 3.0 |
Hyperinsulinism/*blood | 4 | 23.0 |
Biological Markers | 3 | 0.0 |
Prognosis | 3 | 0.0 |
Substrate Specificity | 24 | 1.0 |
Bucladesine/pharmacology | 2 | 1.0 |
Canada | 6 | 4.0 |
Cholesterol Esterase/genetics | 2 | 50.0 |
Forskolin/pharmacology | 2 | 0.0 |
Isoproterenol/pharmacology | 4 | 3.0 |
RNA, Messenger/*genetics | 3 | 0.0 |
Heparin | 31 | 41.0 |
Lipoproteins, VLDL/*metabolism | 29 | 41.0 |
Hyperlipidemia/blood/*genetics | 2 | 25.0 |
Anticoagulants/therapeutic use | 2 | 2.0 |
Heparin/therapeutic use | 2 | 4.0 |
*Diet | 9 | 4.0 |
*Genetic Predisposition to Disease | 4 | 0.0 |
*Neoplasm Proteins | 5 | 0.0 |
*Tumor Suppressor Proteins | 5 | 0.0 |
Cholesterol, Dietary/pharmacology | 2 | 22.0 |
Energy Intake/*physiology | 2 | 15.0 |
Exons/*genetics | 3 | 0.0 |
Mutation, Missense/*genetics | 3 | 1.0 |
*Gene Expression Regulation | 10 | 0.0 |
Dietary Carbohydrates/*administration & dosage | 2 | 8.0 |
Dietary Fats, Unsaturated/*administration & dosage | 3 | 15.0 |
Fatty Acids, Unsaturated/*administration & dosage | 2 | 25.0 |
Leptin/blood | 3 | 5.0 |
Adipocytes/drug effects/metabolism | 2 | 16.0 |
Binding Sites | 30 | 0.0 |
DNA/genetics/metabolism | 2 | 0.0 |
Deoxyribonuclease I/metabolism | 2 | 1.0 |
Promoter Regions (Genetics)/genetics | 3 | 0.0 |
Trans-Activation (Genetics)/*drug effects | 2 | 2.0 |
*Transcription Factors | 2 | 0.0 |
Chromatography, Gel | 13 | 1.0 |
Fibroblasts/metabolism | 7 | 0.0 |
Proteoglycans/*metabolism | 7 | 10.0 |
Blood Pressure | 6 | 0.0 |
Finland/epidemiology | 2 | 1.0 |
Homeostasis | 2 | 0.0 |
Serine | 3 | 3.0 |
Arteriosclerosis/etiology | 7 | 10.0 |
Genetic Screening | 5 | 0.0 |
Hispanic Americans | 4 | 6.0 |
Age Factors | 14 | 0.0 |
Hypertension/epidemiology/*genetics | 2 | 10.0 |
*Linkage (Genetics) | 7 | 0.0 |
Lipoprotein Lipase | 2 | 100.0 |
Nuclear Family | 2 | 0.0 |
Peptidyl-Dipeptidase A/genetics | 2 | 2.0 |
COS Cells/enzymology | 2 | 22.0 |
Immunohistochemistry | 11 | 0.0 |
Infant, Newborn | 9 | 0.0 |
Lipoprotein Lipase/blood/*deficiency/genetics | 5 | 100.0 |
Restriction Mapping | 18 | 0.0 |
African Americans | 2 | 1.0 |
African Continental Ancestry Group/*genetics | 3 | 1.0 |
European Continental Ancestry Group/*genetics | 3 | 0.0 |
Minnesota | 3 | 13.0 |
Mississippi | 2 | 40.0 |
Point Mutation | 13 | 0.0 |
Recombination, Genetic | 3 | 0.0 |
Body Constitution | 7 | 5.0 |
Disease Models, Animal | 9 | 0.0 |
Insulin/metabolism | 5 | 3.0 |
Muscle, Skeletal/metabolism | 6 | 3.0 |
Tumor Necrosis Factor-alpha/metabolism | 3 | 0.0 |
Naphthalenes/pharmacology | 2 | 2.0 |
Neutralization Tests | 2 | 0.0 |
Polysaccharide-Lyases/pharmacology | 6 | 37.0 |
Protein Kinase C/metabolism | 3 | 0.0 |
Adipose Tissue/drug effects/metabolism | 3 | 33.0 |
Muscle, Skeletal/drug effects/metabolism | 2 | 18.0 |
Apolipoproteins E/blood | 5 | 10.0 |
Liver Function Tests | 3 | 1.0 |
DNA, Complementary/chemistry/genetics | 2 | 0.0 |
Mammals | 2 | 0.0 |
Oncorhynchus mykiss/*genetics | 2 | 16.0 |
RNA/genetics | 2 | 1.0 |
Sequence Alignment | 11 | 0.0 |
Enzyme Inhibitors/pharmacology | 6 | 0.0 |
Lipoprotein Lipase/*antagonists & inhibitors/blood | 3 | 100.0 |
Lipoproteins, VLDL/blood/metabolism | 3 | 33.0 |
Lipoprotein Lipase/*deficiency | 9 | 81.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/*genetics | 2 | 8.0 |
Lipase/*genetics | 6 | 17.0 |
Twins, Dizygotic | 3 | 8.0 |
Cholesterol/metabolism | 8 | 2.0 |
Lipoproteins, HDL Cholesterol/metabolism | 4 | 8.0 |
Apolipoprotein A-I/metabolism | 5 | 6.0 |
Apolipoprotein A-II/metabolism | 3 | 21.0 |
Lipoprotein Lipase/*deficiency/genetics | 3 | 100.0 |
DNA Primers/genetics | 7 | 0.0 |
Asian Continental Ancestry Group/genetics | 3 | 0.0 |
China | 5 | 1.0 |
*Chromosome Mapping | 8 | 0.0 |
DNA/genetics | 20 | 1.0 |
Ethnic Groups/*genetics | 3 | 1.0 |
Forensic Medicine | 2 | 3.0 |
Gene Amplification | 5 | 0.0 |
Arteriosclerosis/*enzymology | 4 | 33.0 |
Lipoprotein Lipase/metabolism/*physiology | 3 | 100.0 |
Heymann Nephritis Antigenic Complex | 2 | 9.0 |
Apolipoproteins E/*metabolism | 8 | 7.0 |
Energy Intake | 6 | 3.0 |
Norepinephrine/blood | 2 | 1.0 |
Signal Transduction/*physiology | 2 | 0.0 |
Cell Membrane/*metabolism | 2 | 0.0 |
Cholesterol Esters/metabolism | 8 | 7.0 |
*Membrane Proteins | 2 | 0.0 |
*Receptors, Immunologic | 2 | 1.0 |
Recombinant Proteins/metabolism | 9 | 0.0 |
Chromosomes, Human, Pair 11 | 2 | 0.0 |
Chromosomes, Human, Pair 19 | 2 | 1.0 |
Intervention Studies | 2 | 9.0 |
Lipoproteins/blood/*genetics | 2 | 28.0 |
Apolipoproteins B/genetics | 6 | 16.0 |
Coronary Disease/etiology | 5 | 14.0 |
Multigene Family | 4 | 0.0 |
Hypertension/*genetics | 2 | 1.0 |
Temperature | 6 | 0.0 |
Adipocytes/cytology | 2 | 16.0 |
Deoxyribonuclease HindIII/metabolism | 2 | 28.0 |
Deoxyribonucleases, Type II Site-Specific/metabolism | 4 | 2.0 |
*Polymorphism, Restriction Fragment Length | 22 | 2.0 |
Postmenopause/*physiology | 2 | 8.0 |
Fetus/*metabolism | 2 | 2.0 |
Gluconeogenesis | 2 | 15.0 |
Pregnancy/*metabolism | 4 | 6.0 |
Menopause/*metabolism | 3 | 25.0 |
Premenopause/*metabolism | 2 | 16.0 |
Hypertriglyceridemia/blood/*enzymology/*genetics | 2 | 100.0 |
Lipoprotein Lipase/analysis/*metabolism | 2 | 100.0 |
Cardiovascular Diseases/etiology | 4 | 8.0 |
Obesity/blood | 2 | 5.0 |
Osmolar Concentration | 8 | 1.0 |
Lipoprotein Lipase/*metabolism/pharmacology | 2 | 100.0 |
Lipoproteins, LDL/metabolism | 18 | 8.0 |
Proteoglycans/biosynthesis/chemistry/*metabolism | 2 | 100.0 |
Gene Deletion | 7 | 0.0 |
Apolipoproteins E/blood/genetics | 3 | 18.0 |
Genes, Dominant | 4 | 0.0 |
Lipase/*genetics/metabolism | 2 | 28.0 |
Software | 2 | 0.0 |
Carrier Proteins/analysis | 4 | 4.0 |
Lipoprotein Lipase/analysis | 9 | 81.0 |
Patient Compliance | 2 | 1.0 |
Binding, Competitive | 13 | 0.0 |
Lipoprotein Lipase/chemistry/*metabolism | 4 | 100.0 |
Phospholipases/metabolism | 2 | 11.0 |
African Continental Ancestry Group/genetics | 4 | 1.0 |
Deoxyribonuclease HindIII/genetics | 2 | 33.0 |
*Gene Frequency | 6 | 1.0 |
Serine/genetics | 6 | 7.0 |
Adipocytes/drug effects/*enzymology | 2 | 100.0 |
Enzyme Activation/drug effects | 10 | 1.0 |
Apolipoproteins B/*blood | 7 | 4.0 |
Body Weight/drug effects | 3 | 1.0 |
Placebos | 5 | 2.0 |
Dietary Fats/pharmacokinetics | 2 | 40.0 |
Growth Hormone/*pharmacology | 4 | 5.0 |
RNA, Messenger/*metabolism | 4 | 0.0 |
Hypoglycemic Agents/*therapeutic use | 2 | 3.0 |
Thiazoles/*therapeutic use | 2 | 18.0 |
Confidence Intervals | 2 | 0.0 |
Lipoprotein Lipase/blood/*drug effects | 2 | 100.0 |
Emulsions | 10 | 14.0 |
Fibrinolytic Agents/pharmacology | 2 | 9.0 |
Milk/chemistry | 2 | 13.0 |
Apolipoproteins C/*metabolism | 4 | 66.0 |
Culture Media | 7 | 1.0 |
Iodine Radioisotopes | 6 | 1.0 |
*Lipolysis | 19 | 65.0 |
Lipoproteins, HDL/*metabolism | 13 | 11.0 |
Lipoproteins, VLDL/chemistry/*metabolism | 3 | 30.0 |
Adipose Tissue/*physiology | 2 | 11.0 |
Tumor Necrosis Factor-alpha/*physiology | 2 | 0.0 |
Coronary Disease/*etiology | 2 | 7.0 |
Obesity/*complications | 3 | 17.0 |
*Heterozygote Detection | 4 | 3.0 |
3T3 Cells | 16 | 0.0 |
Adipose Tissue/blood supply | 2 | 50.0 |
Aorta | 7 | 4.0 |
Subcellular Fractions/enzymology | 2 | 2.0 |
Cats | 5 | 1.0 |
*Gene Transfer Techniques | 4 | 1.0 |
*Dietary Fats | 2 | 9.0 |
Hyperlipoproteinemia Type IV/*genetics | 2 | 50.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/metabolism | 5 | 9.0 |
Lipoproteins, HDL Cholesterol/blood/genetics | 2 | 15.0 |
Coronary Disease/*blood | 4 | 6.0 |
Lipoproteins, VLDL/metabolism/*pharmacology | 2 | 66.0 |
Lipoprotein Lipase/genetics/*metabolism/pharmacology | 2 | 100.0 |
Phylogeny | 3 | 0.0 |
Carrier Proteins/*blood | 12 | 4.0 |
Delayed-Action Preparations | 2 | 1.0 |
Injections, Subcutaneous | 5 | 1.0 |
Leptin/*metabolism | 2 | 11.0 |
Pilot Projects | 2 | 0.0 |
Sterol O-Acyltransferase/metabolism | 2 | 10.0 |
Rats, Wistar | 4 | 0.0 |
Receptors, Cytoplasmic and Nuclear/*physiology | 2 | 3.0 |
Transcription Factors/*physiology | 2 | 0.0 |
Fibroblasts | 4 | 0.0 |
Glycosylation | 11 | 1.0 |
Animal Feed | 2 | 11.0 |
Diabetes Mellitus, Experimental/complications/*metabolism | 2 | 66.0 |
Mice, Inbred CBA | 4 | 1.0 |
Conserved Sequence | 5 | 0.0 |
Dogs | 2 | 0.0 |
Species Specificity | 5 | 0.0 |
DNA Fingerprinting/*methods | 2 | 3.0 |
Aorta/pathology | 3 | 7.0 |
Apolipoproteins B/analysis | 3 | 10.0 |
Image Processing, Computer-Assisted | 2 | 0.0 |
Chylomicrons/blood | 16 | 42.0 |
Histamine H1 Antagonists/therapeutic use | 2 | 40.0 |
Lipoprotein Lipase/blood/genetics | 3 | 75.0 |
Lipoprotein Lipase Deficiency, Familial/blood/drug therapy/*etiology | 2 | 100.0 |
Urticaria/blood/*complications/drug therapy | 2 | 100.0 |
Cholesterol/*metabolism | 2 | 0.0 |
Hyperinsulinism/metabolism | 2 | 33.0 |
*Pancreas Transplantation | 2 | 11.0 |
Carnitine O-Palmitoyltransferase/metabolism | 2 | 40.0 |
Fatty Acids/*metabolism | 5 | 5.0 |
Random Allocation | 4 | 0.0 |
Hypertriglyceridemia/*blood | 9 | 23.0 |
DNA, Mitochondrial/*analysis | 2 | 50.0 |
Microsatellite Repeats/*genetics | 4 | 1.0 |
Models, Theoretical | 2 | 1.0 |
Sampling Studies | 3 | 1.0 |
Muscles/enzymology | 8 | 13.0 |
Lipoprotein Lipase/*biosynthesis/drug effects/genetics | 2 | 100.0 |
Receptors, Immunologic/metabolism | 3 | 1.0 |
Transcription Factor AP-1/metabolism | 2 | 0.0 |
Insulin/*therapeutic use | 5 | 6.0 |
Cholesterol/blood/metabolism | 2 | 10.0 |
Asian Continental Ancestry Group | 5 | 1.0 |
Biological Markers/blood | 3 | 0.0 |
Carrier Proteins/*metabolism | 6 | 0.0 |
Hemoglobin A, Glycosylated/metabolism | 4 | 2.0 |
Lipoproteins, LDL/*blood | 7 | 4.0 |
Ultracentrifugation | 9 | 4.0 |
Cholesterol Esters/biosynthesis | 2 | 14.0 |
Mice, Inbred DBA | 2 | 0.0 |
Asparagine/*genetics | 3 | 33.0 |
*Exons | 6 | 1.0 |
Hyperlipidemia/enzymology/*genetics | 2 | 66.0 |
Cell Survival | 2 | 0.0 |
Hydrogen-Ion Concentration | 5 | 0.0 |
Octoxynol/pharmacology | 2 | 3.0 |
Coronary Disease/*genetics | 4 | 6.0 |
*Genes, Structural | 7 | 0.0 |
Methionine/metabolism | 2 | 1.0 |
Protein Biosynthesis | 6 | 0.0 |
*RNA Splicing | 4 | 1.0 |
Adipose Tissue/*drug effects/enzymology | 2 | 100.0 |
Lipoprotein Lipase/*drug effects | 2 | 100.0 |
Liver/*drug effects/enzymology | 2 | 4.0 |
Carrier Proteins/genetics | 6 | 1.0 |
Apolipoproteins E/*physiology | 2 | 6.0 |
Receptors, Lipoprotein/*metabolism | 2 | 12.0 |
Pancreatitis/*etiology | 2 | 25.0 |
*Renal Dialysis | 4 | 0.0 |
Heparin/administration & dosage/*pharmacology | 2 | 15.0 |
Exercise/physiology | 4 | 6.0 |
Genes, Dominant/genetics | 2 | 1.0 |
Chromosome Mapping | 8 | 0.0 |
*Physical Education and Training | 4 | 7.0 |
Fatty Acids, Omega-3/administration & dosage/*pharmacology | 2 | 50.0 |
Gene Expression/drug effects | 3 | 0.0 |
Single-Blind Method | 2 | 0.0 |
Apolipoproteins A/genetics | 4 | 25.0 |
Exercise | 2 | 1.0 |
Heparin Lyase/pharmacology | 2 | 15.0 |
Lipoprotein Lipase/*pharmacology | 6 | 100.0 |
Proteoglycans/*physiology | 3 | 25.0 |
Interferon Type II/*pharmacology | 4 | 0.0 |
Lipoproteins, VLDL/blood/*metabolism | 4 | 40.0 |
alpha-Macroglobulins/metabolism | 4 | 8.0 |
Lipoprotein Lipase/*chemistry | 2 | 100.0 |
Phospholipids/pharmacology | 2 | 6.0 |
Leptin | 3 | 2.0 |
*Nerve Tissue Proteins | 2 | 0.0 |
Dietary Carbohydrates/administration & dosage | 9 | 32.0 |
Gastric Inhibitory Polypeptide/*blood | 2 | 3.0 |
Hormones/pharmacology | 2 | 4.0 |
Adipocytes/enzymology | 3 | 60.0 |
Hyperlipidemia/blood | 5 | 13.0 |
Parenteral Nutrition, Total | 2 | 11.0 |
Microscopy, Electron, Scanning | 2 | 0.0 |
Nutritional Status | 3 | 2.0 |
Hypertriglyceridemia/blood/*genetics | 4 | 57.0 |
Lipoproteins, VLDL/*blood | 14 | 19.0 |
Calorimetry, Indirect | 2 | 3.0 |
Insulin/blood/pharmacology | 2 | 22.0 |
Muscle, Skeletal/drug effects/*enzymology | 2 | 50.0 |
Stimulation, Chemical | 3 | 0.0 |
Apolipoprotein A-I/genetics | 3 | 15.0 |
Coronary Disease/*enzymology | 3 | 33.0 |
DNA/metabolism | 2 | 0.0 |
Embryo | 2 | 0.0 |
Kidney | 4 | 1.0 |
Retinoid X Receptors | 2 | 0.0 |
Transcription, Genetic | 11 | 0.0 |
Blood Chemical Analysis | 2 | 4.0 |
Lactation | 2 | 3.0 |
Lipids/*analysis | 2 | 15.0 |
Gene Dosage | 2 | 0.0 |
Molecular Biology/methods | 2 | 7.0 |
Antibodies, Monoclonal | 13 | 0.0 |
Enzyme-Linked Immunosorbent Assay/*methods | 2 | 1.0 |
Vitamin A/*analogs & derivatives/metabolism | 2 | 50.0 |
Dietary Fats/administration & dosage | 13 | 14.0 |
Colombia | 2 | 4.0 |
DNA Fingerprinting/methods | 4 | 6.0 |
*Tandem Repeat Sequences | 4 | 3.0 |
Adipose Tissue/blood supply/*metabolism | 2 | 100.0 |
Administration, Oral | 5 | 0.0 |
Arteries | 3 | 5.0 |
Injections, Intravenous | 5 | 0.0 |
Veins | 3 | 5.0 |
Insulin/pharmacology | 10 | 3.0 |
Insulin-Like Growth Factor I/pharmacology | 3 | 1.0 |
Recombinant Proteins/pharmacology | 10 | 0.0 |
Apolipoproteins C/*blood | 3 | 9.0 |
Hyperlipoproteinemia/*blood | 7 | 28.0 |
Lipoproteins, HDL/*blood | 25 | 12.0 |
Weight Loss/physiology | 3 | 15.0 |
Transgenes/genetics | 2 | 2.0 |
Antilipemic Agents/*pharmacology | 4 | 10.0 |
Procetofen/analogs & derivatives/pharmacology | 2 | 66.0 |
Chylomicrons/*metabolism | 11 | 33.0 |
Fatty Acids, Nonesterified/*metabolism | 5 | 19.0 |
Endothelium, Vascular/pathology | 2 | 1.0 |
Mice, Inbred Strains | 4 | 0.0 |
Fasting/blood | 2 | 3.0 |
Lipids/*blood/genetics | 3 | 37.0 |
Apolipoproteins/*blood | 5 | 3.0 |
Fatty Acids, Nonesterified/metabolism | 10 | 30.0 |
Antibody Specificity | 4 | 0.0 |
Lipoprotein Lipase/*immunology | 4 | 80.0 |
Models, Molecular | 13 | 0.0 |
Fluorescence | 2 | 0.0 |
Chimeric Proteins/metabolism | 2 | 1.0 |
Cross-Linking Reagents | 2 | 0.0 |
Lipase/genetics/*metabolism | 7 | 63.0 |
Triolein/metabolism | 9 | 90.0 |
DNA, Complementary/chemistry | 2 | 1.0 |
Hyperinsulinism/*metabolism | 2 | 40.0 |
Sequence Homology | 2 | 0.0 |
Adenoviridae/*genetics | 2 | 0.0 |
In Situ Hybridization | 5 | 0.0 |
Apolipoproteins/genetics | 3 | 13.0 |
Linkage Disequilibrium/*genetics | 2 | 2.0 |
Receptors, LDL/genetics | 2 | 2.0 |
*CCAAT-Enhancer-Binding Proteins | 2 | 1.0 |
Gene Expression Regulation/drug effects | 4 | 0.0 |
*Promoter Regions (Genetics) | 9 | 0.0 |
Regulatory Sequences, Nucleic Acid | 3 | 0.0 |
Arteriosclerosis/*enzymology/etiology | 2 | 100.0 |
Hypertriglyceridemia/complications | 2 | 25.0 |
Lipoprotein Lipase/drug effects/metabolism | 2 | 100.0 |
*Chromosomes, Human, Pair 8 | 9 | 3.0 |
Alberta | 3 | 33.0 |
Aryldialkylphosphatase | 3 | 1.0 |
Esterases/genetics | 2 | 11.0 |
Lipoprotein Lipase/biosynthesis | 3 | 100.0 |
Liver/*metabolism | 7 | 1.0 |
Pancreatitis/etiology | 4 | 44.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/blood | 4 | 5.0 |
Adipocytes/*metabolism | 3 | 6.0 |
Skin | 5 | 6.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/*blood | 7 | 6.0 |
Lipoprotein Lipase Deficiency, Familial/blood/*genetics | 4 | 100.0 |
Lipolysis/*physiology | 5 | 50.0 |
Odds Ratio | 5 | 0.0 |
*Coronary Angiography | 2 | 8.0 |
Obesity/metabolism | 3 | 6.0 |
Apolipoproteins B/*genetics | 3 | 1.0 |
Carcinoma, Hepatocellular/metabolism | 2 | 2.0 |
Cholesterol Esters/*metabolism | 5 | 5.0 |
Liver/cytology/*metabolism | 4 | 5.0 |
Milk/enzymology | 20 | 83.0 |
Skin/*metabolism | 2 | 1.0 |
Tritium | 3 | 1.0 |
Haplotypes/*genetics | 2 | 1.0 |
Likelihood Functions | 3 | 1.0 |
Linkage (Genetics)/genetics | 3 | 1.0 |
*Sex Characteristics | 3 | 2.0 |
Enzyme Inhibitors/*pharmacology | 4 | 0.0 |
Gene Expression/*drug effects | 2 | 0.0 |
Monocytes/enzymology | 2 | 6.0 |
Colon/*immunology | 3 | 13.0 |
Epithelium/immunology | 2 | 1.0 |
Flow Cytometry | 4 | 0.0 |
Apoproteins/blood | 3 | 15.0 |
Lipoprotein(a)/blood | 2 | 3.0 |
Biopsy | 4 | 0.0 |
Insulin Resistance/physiology | 4 | 8.0 |
Metabolic Clearance Rate | 5 | 1.0 |
Cellulose/*analogs & derivatives | 2 | 16.0 |
Kidney Failure, Chronic/blood/therapy | 2 | 6.0 |
Membranes, Artificial | 2 | 2.0 |
Renal Dialysis | 10 | 3.0 |
Monocytes/*metabolism | 2 | 0.0 |
Diabetes Complications | 2 | 1.0 |
Nephelometry and Turbidimetry | 2 | 2.0 |
Hypertriglyceridemia/enzymology/*etiology | 2 | 100.0 |
Apolipoproteins A/*blood | 2 | 4.0 |
Thyrotropin/blood | 2 | 0.0 |
Adipose Tissue/cytology/enzymology/*metabolism | 2 | 100.0 |
Mice, Obese | 3 | 6.0 |
Rats, Zucker | 4 | 16.0 |
Hyperlipoproteinemia Type III/*blood/genetics | 2 | 66.0 |
Lipoproteins, VLDL/pharmacology | 4 | 25.0 |
Vitamin A/analogs & derivatives/blood | 3 | 50.0 |
Anticoagulants/pharmacology | 5 | 7.0 |
Liver/drug effects/enzymology | 3 | 4.0 |
Lipids/biosynthesis | 3 | 15.0 |
DNA-Binding Proteins/metabolism | 3 | 0.0 |
Sequence Homology, Nucleic Acid | 7 | 0.0 |
Artifacts | 2 | 3.0 |
Immunoglobulin G/immunology | 2 | 0.0 |
Lipoprotein Lipase/*analysis/genetics | 2 | 100.0 |
Fluorescent Antibody Technique | 7 | 0.0 |
Microscopy, Confocal | 3 | 0.0 |
Microscopy, Immunoelectron | 3 | 0.0 |
Models, Biological | 18 | 0.0 |
Arginine/genetics | 2 | 1.0 |
Glycine/genetics | 4 | 4.0 |
Genetic Heterogeneity | 2 | 0.0 |
Chickens | 7 | 0.0 |
Lipoprotein Lipase/*chemistry/genetics/*metabolism | 3 | 100.0 |
DNA Primers/chemistry | 4 | 0.0 |
Macrophages/drug effects/*enzymology | 5 | 50.0 |
RNA, Messenger/analysis/genetics | 3 | 0.0 |
Half-Life | 5 | 0.0 |
Demography | 2 | 1.0 |
Netherlands/epidemiology | 2 | 1.0 |
India/ethnology | 2 | 2.0 |
*Introns | 3 | 1.0 |
Apolipoproteins C/metabolism/pharmacology | 3 | 100.0 |
Cholesterol/*pharmacology | 3 | 15.0 |
*Emulsions | 2 | 66.0 |
Recombinant Proteins/genetics/metabolism | 4 | 0.0 |
Radioligand Assay | 3 | 0.0 |
Gene Therapy | 4 | 1.0 |
*Genetic Vectors | 2 | 0.0 |
LDL-Receptor Related Protein 1 | 16 | 14.0 |
Lipoprotein Lipase/analysis/*genetics/metabolism | 2 | 100.0 |
Recombinant Proteins | 3 | 0.0 |
Insulin Resistance/*genetics | 2 | 2.0 |
*Kidney Transplantation | 2 | 0.0 |
Lipids/analysis/blood | 2 | 50.0 |
Lipoprotein Lipase/analysis/*blood | 2 | 100.0 |
Enzyme Induction/drug effects | 2 | 0.0 |
Adenoviridae/genetics | 5 | 1.0 |
Genetic Vectors/genetics | 2 | 0.0 |
Lipoprotein Lipase/deficiency/*genetics/metabolism | 5 | 100.0 |
Body Constitution/*physiology | 2 | 15.0 |
Hypertriglyceridemia/*metabolism | 2 | 16.0 |
Lipoprotein Lipase/*analysis | 10 | 100.0 |
Linkage Disequilibrium/genetics | 3 | 1.0 |
Antibodies, Monoclonal/pharmacology | 3 | 0.0 |
Protein Denaturation | 3 | 1.0 |
*Obesity | 2 | 3.0 |
Adipocytes/cytology/*metabolism | 2 | 16.0 |
Chloroquine/pharmacology | 5 | 6.0 |
Epinephrine/pharmacology | 5 | 5.0 |
Physical Endurance/*physiology | 2 | 4.0 |
*Physical Fitness | 2 | 5.0 |
Thigh | 2 | 7.0 |
Apolipoproteins C/blood | 3 | 10.0 |
Blood Protein Electrophoresis | 2 | 1.0 |
Enzyme Activation/physiology | 3 | 1.0 |
Chylomicrons/*blood/*genetics | 2 | 100.0 |
Lipase/*deficiency | 3 | 50.0 |
Asparagine/genetics | 4 | 10.0 |
Aspartic Acid/genetics | 3 | 4.0 |
France/ethnology | 6 | 15.0 |
Hyperlipidemia/*chemically induced | 3 | 75.0 |
Lipoprotein Lipase/antagonists & inhibitors/*blood | 3 | 100.0 |
Perfusion | 4 | 1.0 |
*DNA Transposable Elements | 2 | 3.0 |
Papio | 2 | 1.0 |
*Repetitive Sequences, Nucleic Acid | 3 | 0.0 |
Muscles/*enzymology | 12 | 15.0 |
Fatty Acids, Omega-3/*therapeutic use | 2 | 20.0 |
Macrophages/enzymology | 6 | 18.0 |
Heat | 2 | 0.0 |
Heparin Lyase | 5 | 31.0 |
Lactones/pharmacology | 2 | 5.0 |
Glucose Clamp Technique | 4 | 3.0 |
Lipoprotein Lipase/*blood/*genetics | 2 | 100.0 |
Pravastatin/therapeutic use | 2 | 12.0 |
Apolipoproteins C/blood/*genetics | 2 | 25.0 |
Sequence Analysis, DNA/*methods | 2 | 3.0 |
Heparitin Sulfate/*metabolism | 6 | 20.0 |
Apolipoproteins/analysis/metabolism | 2 | 66.0 |
Lipoproteins, VLDL/blood/isolation & purification/*metabolism | 3 | 100.0 |
Triglycerides/analysis/metabolism | 3 | 42.0 |
Heparin/diagnostic use | 4 | 44.0 |
Macromolecular Substances | 3 | 0.0 |
Lipoproteins/*blood/genetics | 2 | 22.0 |
Hyperlipidemia, Familial Combined/*genetics | 3 | 25.0 |
Fatty Acids/biosynthesis | 2 | 50.0 |
Arteriosclerosis/blood/*genetics | 2 | 28.0 |
Apolipoproteins A/blood | 9 | 13.0 |
*Diet, Reducing | 6 | 8.0 |
Endothelium, Vascular/*physiopathology | 2 | 2.0 |
Forearm/blood supply | 2 | 4.0 |
Lipoproteins/blood/metabolism | 2 | 11.0 |
Triglycerides/*blood/*metabolism | 2 | 66.0 |
Drug Administration Schedule | 2 | 0.0 |
Radioimmunoassay | 3 | 0.0 |
Receptors, Immunologic/*metabolism | 9 | 4.0 |
Receptors, LDL/*metabolism | 8 | 8.0 |
alpha-Macroglobulins/*metabolism | 5 | 15.0 |
Cytoplasm/metabolism | 2 | 0.0 |
Muscle Proteins/metabolism | 2 | 4.0 |
Chromatography, Thin Layer | 2 | 1.0 |
*Homozygote | 3 | 1.0 |
Body Height | 3 | 1.0 |
Femur | 3 | 15.0 |
Protein Processing, Post-Translational | 2 | 0.0 |
Triglycerides/chemistry/metabolism | 2 | 40.0 |
Foam Cells/metabolism | 2 | 15.0 |
Precipitation | 2 | 1.0 |
Blood Proteins/*biosynthesis | 2 | 15.0 |
*Complement 3a/*analogs & derivatives | 2 | 10.0 |
Feedback | 3 | 1.0 |
Glutamic Acid | 4 | 5.0 |
Glycine | 5 | 6.0 |
Tryptophan | 2 | 7.0 |
Apolipoproteins E/*blood | 4 | 7.0 |
Dietary Fats/*pharmacology | 3 | 4.0 |
Clinical Trials | 2 | 0.0 |
Glycerol/blood | 5 | 12.0 |
Dietary Carbohydrates/*pharmacology | 2 | 9.0 |
Eating/*physiology | 4 | 5.0 |
DNA | 7 | 0.0 |
Lipoprotein Lipase/chemistry/genetics/*metabolism | 3 | 100.0 |
*Genes | 2 | 0.0 |
Lipoprotein Lipase/*chemistry/genetics/metabolism | 4 | 100.0 |
Receptors, Cell Surface/*metabolism | 3 | 0.0 |
DNA, Complementary | 6 | 0.0 |
Liver/drug effects/metabolism | 4 | 5.0 |
Nucleic Acid Hybridization | 15 | 0.0 |
Fibroblasts/cytology/metabolism | 2 | 1.0 |
Triglycerides/analysis/*metabolism | 3 | 60.0 |
Vitamin A/metabolism | 2 | 10.0 |
Densitometry | 2 | 1.0 |
Fasting/metabolism | 3 | 17.0 |
Lipoprotein Lipase/blood/*deficiency | 2 | 100.0 |
Lipoprotein Lipase/blood/metabolism | 3 | 100.0 |
Mammals/genetics | 2 | 3.0 |
*Protein Biosynthesis | 2 | 0.0 |
Cell Membrane/chemistry | 2 | 1.0 |
Proteoglycans/metabolism | 5 | 6.0 |
Cycloheximide/pharmacology | 4 | 0.0 |
Lipoprotein Lipase/*biosynthesis/genetics/metabolism | 2 | 100.0 |
Lipoproteins, VLDL/isolation & purification/*metabolism | 2 | 100.0 |
Recombinant Fusion Proteins/metabolism | 2 | 0.0 |
Skin/metabolism | 2 | 1.0 |
Lipoproteins, LDL/blood/*genetics | 2 | 33.0 |
Immunoenzyme Techniques | 6 | 0.0 |
Fatty Acids/*pharmacology | 2 | 7.0 |
Phospholipids/blood | 11 | 8.0 |
Carcinoma, Hepatocellular | 2 | 0.0 |
Liver Neoplasms | 2 | 0.0 |
Oleic Acid | 5 | 8.0 |
Oleic Acids/pharmacology | 3 | 14.0 |
Apolipoproteins E/*pharmacology | 2 | 8.0 |
Cholesterol Esters/blood/metabolism | 2 | 28.0 |
Carbon Radioisotopes | 3 | 3.0 |
Sulfur Radioisotopes | 3 | 4.0 |
Triglycerides/biosynthesis/metabolism | 2 | 50.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 10 | 0.0 |
Antigen-Antibody Reactions | 2 | 0.0 |
Lipase/*physiology | 5 | 62.0 |
Amino Acid Sequence/genetics | 2 | 0.0 |
Hyperlipidemia, Familial Combined/enzymology/*genetics | 2 | 100.0 |
Hyperlipoproteinemia Type IV/enzymology/*genetics | 2 | 100.0 |
Lipoprotein Lipase/deficiency/*genetics | 14 | 100.0 |
Blood Proteins/metabolism | 2 | 0.0 |
Glucocorticoids/*pharmacology | 2 | 1.0 |
Rats, Inbred Strains | 15 | 1.0 |
Fluorescent Dyes | 2 | 0.0 |
Hypertriglyceridemia/etiology | 2 | 66.0 |
Lipase/*antagonists & inhibitors | 3 | 37.0 |
Lipoproteins, HDL/*blood/isolation & purification | 2 | 20.0 |
Macrophages/metabolism | 4 | 1.0 |
*Protein Structure, Secondary | 2 | 1.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Lipoproteins/blood/chemistry | 2 | 18.0 |
Receptors, Immunologic/*physiology | 2 | 1.0 |
Diabetes Mellitus, Type 2/blood | 2 | 5.0 |
Heparin/administration & dosage/pharmacology | 2 | 50.0 |
Myocardial Infarction/*blood/*genetics | 2 | 50.0 |
Absorption | 2 | 1.0 |
Blood/metabolism | 2 | 5.0 |
Regional Blood Flow | 2 | 1.0 |
Oxidative Stress | 2 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 6 | 0.0 |
Lipoproteins/chemistry/*metabolism | 2 | 15.0 |
Cell Division/drug effects | 3 | 0.0 |
Dexamethasone/pharmacology | 4 | 0.0 |
Lipoprotein Lipase Deficiency, Familial/enzymology/*genetics | 6 | 100.0 |
Heparan Sulfate Proteoglycan | 5 | 15.0 |
Heparitin Sulfate/metabolism | 2 | 5.0 |
Cell-Free System | 3 | 1.0 |
Hyperlipidemia, Familial Combined/*blood | 3 | 33.0 |
Pancreatitis/*genetics | 2 | 5.0 |
Cell Compartmentation | 2 | 0.0 |
Protease Inhibitors/pharmacology | 3 | 1.0 |
Extracellular Matrix/drug effects/*metabolism | 2 | 20.0 |
Lipoproteins, HDL/blood/isolation & purification/pharmacology | 2 | 100.0 |
Apolipoproteins B/*analysis | 2 | 7.0 |
Lipoprotein Lipase/isolation & purification/*metabolism | 4 | 100.0 |
Arteriosclerosis/*enzymology/pathology | 2 | 40.0 |
Down-Regulation | 2 | 0.0 |
Monocytes/cytology | 3 | 2.0 |
Hyperlipidemia, Familial Combined/blood/enzymology/*genetics | 2 | 100.0 |
*Antibodies, Monoclonal | 2 | 0.0 |
Lipoprotein Lipase/classification/*genetics | 2 | 100.0 |
Guanidines/pharmacology | 2 | 4.0 |
Evaluation Studies | 2 | 0.0 |
Rats, Inbred F344 | 2 | 0.0 |
Hybrid Cells | 3 | 0.0 |
Sheep/*genetics | 2 | 3.0 |
Adipose Tissue/pathology | 2 | 6.0 |
Animals, Newborn | 3 | 0.0 |
Tunicamycin/pharmacology | 3 | 3.0 |
Receptors, LDL/physiology | 4 | 22.0 |
Receptors, LDL/analysis | 2 | 18.0 |
Apolipoprotein A-II/blood | 2 | 10.0 |
Glycoproteins/blood | 3 | 5.0 |
Lipoprotein Lipase/*biosynthesis | 8 | 100.0 |
RNA, Messenger/genetics/*metabolism | 2 | 1.0 |
Combined Modality Therapy | 3 | 0.0 |
Octreotide/*therapeutic use | 2 | 5.0 |
Phospholipids/metabolism | 2 | 1.0 |
Asparagine/chemistry | 2 | 11.0 |
Protamines | 2 | 28.0 |
Hypertriglyceridemia/blood | 5 | 20.0 |
Serum Albumin/metabolism | 3 | 1.0 |
Mesocricetus | 2 | 1.0 |
Sheep | 3 | 0.0 |
DNA-Binding Proteins/genetics/*metabolism | 2 | 0.0 |
Transcription Factors/genetics/*metabolism | 2 | 0.0 |
Longevity | 2 | 10.0 |
Extracellular Matrix/metabolism | 2 | 1.0 |
Coronary Disease/blood | 3 | 10.0 |
Evolution | 2 | 0.0 |
Lipoprotein Lipase/*chemistry/*genetics/metabolism | 2 | 100.0 |
Blood Pressure/drug effects | 3 | 0.0 |
Drug Therapy, Combination | 3 | 0.0 |
Cachexia/etiology/*metabolism | 2 | 40.0 |
Transcription Factors/metabolism | 2 | 0.0 |
Lipoprotein Lipase Deficiency, Familial/*blood | 2 | 100.0 |
RNA, Messenger/analysis/biosynthesis | 2 | 0.0 |
*Mutagenesis, Site-Directed | 4 | 4.0 |
Lipoprotein Lipase/*genetics/physiology | 2 | 66.0 |
Lipoprotein Lipase/drug effects/*metabolism | 2 | 100.0 |
Organ Size | 3 | 1.0 |
Hydrocortisone/pharmacology | 2 | 2.0 |
Lipoprotein Lipase/*antagonists & inhibitors/genetics | 3 | 100.0 |
Eating | 4 | 2.0 |
Lipoprotein Lipase/*blood/metabolism | 2 | 66.0 |
Eating/physiology | 2 | 3.0 |
Phosphatidylcholines/blood | 2 | 9.0 |
Oligonucleotide Probes/genetics | 2 | 1.0 |
*Exertion | 6 | 3.0 |
Gemfibrozil/*therapeutic use | 3 | 12.0 |
Fatty Acids, Nonesterified/*blood | 6 | 12.0 |
Glycerol/*blood | 2 | 100.0 |
Oligodeoxyribonucleotides | 7 | 0.0 |
Plasmids | 4 | 0.0 |
Chromatography | 3 | 1.0 |
Lipoprotein Lipase Deficiency, Familial/*enzymology | 4 | 100.0 |
Monocytes/*enzymology | 2 | 7.0 |
Hela Cells | 2 | 0.0 |
Hypertriglyceridemia/enzymology/*genetics | 2 | 50.0 |
Ethnic Groups | 3 | 1.0 |
Carbohydrates/metabolism | 2 | 3.0 |
Randomized Controlled Trials | 2 | 0.0 |
Lipid Mobilization/physiology | 2 | 100.0 |
Infusions, Parenteral | 2 | 1.0 |
Genes, Recessive | 5 | 1.0 |
Xanthomatosis/etiology | 2 | 40.0 |
Endothelium, Vascular/enzymology | 2 | 4.0 |
*Codon | 2 | 4.0 |
Computer Simulation | 3 | 0.0 |
DNA/analysis/chemistry | 4 | 18.0 |
Ethanol/*pharmacology | 4 | 3.0 |
Lipoproteins, HDL/*blood/genetics | 2 | 50.0 |
RNA, Messenger/*analysis | 4 | 0.0 |
Hyperlipoproteinemia Type III/metabolism | 2 | 66.0 |
Adipose Tissue/cytology/drug effects/*enzymology | 2 | 66.0 |
Cytokines/*pharmacology | 2 | 0.0 |
DNA Probes | 2 | 0.0 |
Interferon Type I, Recombinant/pharmacology | 2 | 6.0 |
Interleukin-1/pharmacology | 2 | 0.0 |
Epitopes | 2 | 0.0 |
Amino Acids/analysis | 3 | 1.0 |
Liver Neoplasms, Experimental/metabolism | 2 | 10.0 |
Tumor Cells, Cultured/metabolism | 2 | 1.0 |
Codon/genetics | 3 | 0.0 |
*Eating | 5 | 8.0 |
Apolipoproteins/analysis | 3 | 11.0 |
Gene Rearrangement | 2 | 0.0 |
Pancreatitis/complications | 2 | 25.0 |
Lipoproteins, HDL/blood/*genetics | 2 | 33.0 |
Apolipoprotein A-I/analysis | 3 | 15.0 |
Cell Division | 2 | 0.0 |
Serine/metabolism | 3 | 0.0 |
Arteriosclerosis/enzymology | 3 | 30.0 |
Hyperlipidemia/enzymology | 2 | 66.0 |
Lipoprotein Lipase/*chemistry/genetics/*physiology | 2 | 100.0 |
Body Composition/*drug effects | 2 | 15.0 |
Hormones/blood | 2 | 1.0 |
Stereoisomerism | 2 | 0.0 |
Lipoprotein(a)/*blood | 3 | 3.0 |
Antilipemic Agents/therapeutic use | 3 | 10.0 |
Lipoprotein Lipase Deficiency, Familial/ethnology/*genetics | 3 | 100.0 |
Kidney Failure, Chronic/*blood/therapy | 2 | 3.0 |
Mice, Inbred ICR | 2 | 0.0 |
Lipase/*chemistry/genetics/*metabolism | 2 | 100.0 |
*Glycine | 3 | 15.0 |
*Serine | 4 | 11.0 |
Louisiana | 2 | 10.0 |
Adipose Tissue/drug effects/*enzymology | 6 | 85.0 |
Dexamethasone/*pharmacology | 3 | 1.0 |
Gene Expression Regulation, Enzymologic/*drug effects | 2 | 1.0 |
Organ Culture Techniques | 2 | 0.0 |
Cell Differentiation/drug effects | 4 | 0.0 |
Lipoprotein Lipase/chemistry/*genetics/metabolism | 3 | 100.0 |
Lipoprotein Lipase/*blood/isolation & purification | 5 | 100.0 |
Carcinoma, Hepatocellular/enzymology | 2 | 11.0 |
DNA-Binding Proteins/*metabolism | 2 | 0.0 |
Liver Neoplasms/enzymology | 2 | 14.0 |
Hyperinsulinism/complications | 2 | 20.0 |
Coronary Disease/prevention & control | 2 | 20.0 |
Placenta/metabolism | 2 | 1.0 |
Kidney/metabolism | 2 | 0.0 |
Simvastatin | 2 | 6.0 |
Iodine Radioisotopes/diagnostic use | 2 | 0.0 |
Obesity/*blood | 2 | 2.0 |
Tritium/diagnostic use | 3 | 2.0 |
Specimen Handling/*methods | 2 | 10.0 |
Hyperlipoproteinemia Type IV/*metabolism | 2 | 100.0 |
Lipids/analysis | 2 | 4.0 |
DNA/blood/genetics/isolation & purification | 3 | 7.0 |
Leukocytes/enzymology | 3 | 2.0 |
Genes, Structural | 4 | 0.0 |
Chromatography, Agarose | 4 | 8.0 |
Epididymis/enzymology | 2 | 33.0 |
Lipoproteins, VLDL/*blood/chemistry/isolation & purification | 2 | 100.0 |
Sepharose/analogs & derivatives | 2 | 10.0 |
Methods | 5 | 2.0 |
Hypolipoproteinemia/*blood | 2 | 9.0 |
Apolipoproteins C/deficiency | 2 | 100.0 |
Diagnosis, Differential | 3 | 0.0 |
Lipoprotein Lipase Deficiency, Familial/epidemiology/*genetics | 3 | 100.0 |
Apolipoproteins C/pharmacology | 2 | 100.0 |
*Heparin | 3 | 23.0 |
Lipase/antagonists & inhibitors/*blood | 2 | 100.0 |
Sodium Chloride/pharmacology | 4 | 5.0 |
Triolein | 3 | 50.0 |
Lipoprotein Lipase/pharmacology | 2 | 100.0 |
Dietary Fats/*administration & dosage/metabolism | 2 | 22.0 |
Chemical Fractionation | 3 | 4.0 |
Cellulose | 2 | 16.0 |
Genetic Predisposition to Disease/epidemiology | 2 | 2.0 |
Fatty Acids, Nonesterified/*pharmacology | 2 | 22.0 |
Milk/*enzymology | 3 | 75.0 |
Apoproteins/*blood | 2 | 15.0 |
Serum Albumin/analysis | 2 | 1.0 |
Lipoprotein Lipase/antagonists & inhibitors | 2 | 40.0 |
Macaca fascicularis | 3 | 1.0 |
DNA, Single-Stranded | 3 | 3.0 |
Adipose Tissue/*cytology/metabolism | 2 | 66.0 |
Creatinine/blood | 2 | 0.0 |
Uric Acid/blood | 2 | 3.0 |
Repetitive Sequences, Nucleic Acid/*genetics | 2 | 1.0 |
Adipose Tissue/cytology/*enzymology | 5 | 71.0 |
Peptide Fragments/analysis | 2 | 0.0 |
Interferon-gamma, Recombinant/pharmacology | 2 | 1.0 |
Lipase/blood/*metabolism | 4 | 80.0 |
Lipoprotein Lipase/analysis/*physiology | 2 | 100.0 |
Calcium/metabolism | 3 | 0.0 |
Oleic Acids/metabolism | 2 | 9.0 |
Cytotoxicity, Immunologic/*immunology | 2 | 4.0 |
HIV/growth & development | 2 | 33.0 |
HIV Infections/*immunology | 2 | 0.0 |
Intestinal Mucosa/*immunology | 2 | 2.0 |
Killer Cells, Lymphokine-Activated/immunology | 2 | 3.0 |
Killer Cells, Natural/immunology | 2 | 0.0 |
Lymphocyte Subsets/immunology | 2 | 1.0 |
Lymphocytes/*immunology/microbiology | 2 | 66.0 |
Glutamine/genetics | 2 | 4.0 |
Interleukin-1/*pharmacology | 5 | 1.0 |
Stem Cells/*cytology | 2 | 2.0 |
Muscle, Smooth, Vascular/enzymology | 2 | 25.0 |
Asparagine/metabolism | 2 | 15.0 |
Cross Reactions | 2 | 0.0 |
DNA/genetics/isolation & purification | 2 | 0.0 |
Diabetes Mellitus/drug therapy/*enzymology | 2 | 66.0 |
Sulfonylurea Compounds/*therapeutic use | 2 | 11.0 |
Isoelectric Focusing | 3 | 0.0 |
Obesity/diet therapy/*metabolism | 2 | 28.0 |
Drug Combinations | 3 | 0.0 |
Blood Pressure/physiology | 2 | 1.0 |
*Circadian Rhythm | 3 | 1.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/*metabolism | 2 | 3.0 |
Cholesterol/analysis | 2 | 4.0 |
RNA, Messenger/drug effects | 2 | 3.0 |
Dactinomycin/pharmacology | 2 | 0.0 |
Transcription, Genetic/*drug effects | 2 | 0.0 |
Muscles/*metabolism | 3 | 4.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
*Fasting | 2 | 8.0 |
Freezing | 2 | 2.0 |
Insulin/*physiology | 2 | 4.0 |
Milk, Human/*enzymology | 4 | 50.0 |
Apolipoprotein A-II | 8 | 17.0 |
Tangier Disease/*blood | 2 | 33.0 |
Melanoma/complications/*metabolism | 2 | 100.0 |
Biopsy, Needle | 2 | 0.0 |
Phenobarbital/*pharmacology | 2 | 11.0 |
Triglycerides/*blood/metabolism | 2 | 18.0 |
Oligonucleotide Probes | 2 | 0.0 |
*Adaptation, Physiological | 2 | 3.0 |
Lipase/*blood/immunology | 2 | 100.0 |
Lipoprotein Lipase/*blood/immunology | 4 | 100.0 |
Obesity/genetics | 3 | 5.0 |
Oligonucleotides | 2 | 3.0 |
Twins, Monozygotic | 3 | 3.0 |
*Food | 3 | 3.0 |
Lipoprotein Lipase/*metabolism/secretion | 2 | 100.0 |
Secretory Rate/drug effects | 2 | 2.0 |
Hyperlipoproteinemia/*enzymology | 5 | 100.0 |
Adipose Tissue/enzymology/*metabolism | 3 | 75.0 |
Immunosorbent Techniques | 2 | 0.0 |
Lipase/*pharmacology | 2 | 66.0 |
Triglycerides | 7 | 77.0 |
*Cloning, Molecular | 2 | 0.0 |
Apolipoproteins C/*pharmacology | 2 | 40.0 |
Heparin, Low-Molecular-Weight/*pharmacology | 3 | 18.0 |
Apolipoprotein A-I | 10 | 9.0 |
Skinfold Thickness | 2 | 2.0 |
Heparin/administration & dosage | 4 | 17.0 |
Immunochemistry | 4 | 1.0 |
Procetofen/*therapeutic use | 2 | 12.0 |
Diabetes Mellitus/*metabolism | 2 | 5.0 |
Gene Expression Regulation, Enzymologic/drug effects | 2 | 1.0 |
Hyperlipoproteinemia Type IV/blood | 2 | 20.0 |
Postmenopause/blood | 2 | 6.0 |
Lipoprotein Lipase Deficiency, Familial/*blood/complications | 2 | 100.0 |
Apolipoproteins A/metabolism | 2 | 11.0 |
Detergents | 2 | 1.0 |
Menopause | 4 | 1.0 |
Epididymis | 2 | 22.0 |
Lipase/*analysis | 3 | 100.0 |
Pulmonary Surfactants/metabolism | 2 | 16.0 |
Adipose Tissue/analysis | 3 | 60.0 |
Endothelium, Vascular/*enzymology | 2 | 4.0 |
Lipoprotein Lipase/immunology/*metabolism | 3 | 100.0 |
Serum Albumin, Bovine/pharmacology | 2 | 6.0 |
Phosphatidylcholines/*metabolism | 4 | 8.0 |
Phospholipases/*metabolism | 2 | 16.0 |
Endothelium, Vascular/drug effects/enzymology | 2 | 40.0 |
Heparitin Sulfate/pharmacology | 2 | 15.0 |
Blood Coagulation/drug effects | 2 | 1.0 |
Staining and Labeling | 2 | 0.0 |
Recombinant Proteins/*pharmacology | 2 | 2.0 |
Arteriosclerosis/enzymology/metabolism | 2 | 100.0 |
Estradiol/blood | 2 | 0.0 |
Lipase/blood/metabolism | 2 | 100.0 |
Lipids/blood/*metabolism | 2 | 11.0 |
Apolipoprotein A-I/blood/genetics | 2 | 33.0 |
Receptors, Cell Surface/physiology | 2 | 1.0 |
Thyroid Hormones/*blood | 2 | 3.0 |
Triiodothyronine/blood | 4 | 1.0 |
Hyperlipidemia/*etiology/metabolism | 2 | 66.0 |
*Genetic Markers | 2 | 0.0 |
Triolein/pharmacology | 2 | 100.0 |
Factor X/antagonists & inhibitors | 3 | 33.0 |
Factor Xa | 4 | 21.0 |
Tamoxifen/*adverse effects | 2 | 28.0 |
Hypercholesterolemia, Familial/blood | 2 | 12.0 |
Phosphatidylcholines/metabolism | 3 | 3.0 |
Maternal-Fetal Exchange | 2 | 1.0 |
Pulmonary Alveoli/cytology | 2 | 9.0 |
Lipoprotein Lipase Deficiency, Familial/*blood/enzymology/genetics | 2 | 100.0 |
*Body Weight | 2 | 3.0 |
Lipoprotein Lipase/deficiency | 2 | 100.0 |
Hyperlipoproteinemia Type V/blood | 2 | 40.0 |
Postprandial Period/physiology | 2 | 11.0 |
Africa/ethnology | 2 | 4.0 |
DNA/chemistry/genetics | 2 | 0.0 |
Triglycerides/analysis | 2 | 6.0 |
Circadian Rhythm | 2 | 0.0 |
Levonorgestrel | 3 | 9.0 |
Liver Cirrhosis/enzymology | 2 | 18.0 |
Spectrometry, Fluorescence | 4 | 0.0 |
Diet, Reducing | 2 | 6.0 |
Antibodies | 2 | 0.0 |
*Apolipoproteins C | 10 | 62.0 |
Apolipoproteins/pharmacology | 3 | 75.0 |
Erythrocytes/metabolism | 2 | 1.0 |
*Glucose Tolerance Test | 2 | 3.0 |
*Sports | 2 | 6.0 |
*Weight Lifting | 2 | 16.0 |
Coronary Disease/physiopathology | 2 | 12.0 |
Hyperlipidemia/physiopathology | 2 | 50.0 |
Lipoproteins, HDL Cholesterol | 9 | 19.0 |
Lipoproteins, LDL Cholesterol | 5 | 20.0 |
Physical Education and Training | 2 | 8.0 |
Physical Endurance | 2 | 6.0 |
Hyperlipidemia/*blood | 2 | 5.0 |
Thyroid Function Tests | 2 | 2.0 |
Hypercholesterolemia, Familial/enzymology | 2 | 100.0 |
Apolipoproteins/*pharmacology | 3 | 50.0 |
Growth Hormone/blood | 2 | 0.0 |
Chronic Disease | 2 | 0.0 |
*Parenteral Nutrition | 3 | 15.0 |
*Parenteral Nutrition, Total | 2 | 3.0 |
Apolipoproteins/blood/*deficiency | 2 | 100.0 |
Genetics, Population/*methods | 2 | 50.0 |
Protein Structure, Secondary | 2 | 0.0 |
Cell Separation | 2 | 0.0 |
Smoking/epidemiology | 2 | 3.0 |
Hyperlipidemia/*enzymology | 2 | 50.0 |
Renal Dialysis/*adverse effects | 2 | 1.0 |
Chromatography, Affinity/methods | 2 | 2.0 |
Lipase/*blood/isolation & purification | 2 | 100.0 |
Clofibrate/*pharmacology | 2 | 50.0 |
Esterases/*blood | 2 | 11.0 |
Electrochemistry/*methods | 2 | 22.0 |
Environment | 2 | 2.0 |
